PD

SlackBytes

Pagerduty $PD. It’s only $1.4B market cap. It’s a tech company and they have no competition. They specialize in paging systems. And well I guess every company needs some users with it and they’ll eventually adapt Pagerduty.

Nusanss

they're actually showing slightly better numbers than the current standard. Casdozokitug combo is showing 38% overall response rate with 17% complete responses in liver cancer. Keytruda + Avastin (current standard) shows \~36% response with \~12% complete responses. So marginally better, but here's the real play: They're attacking different mechanisms. Keytruda blocks PD-1 (removes the brakes on immune cells). Casdozokitug blocks IL-27 (removes the tumor's "invisibility cloak"). CHS-114 kills regulatory T-cells that protect the tumor. Think of it like this - Keytruda is a sledgehammer that works great for some patients. Coherus is building targeted tools for the 60%+ who don't respond to Keytruda. The smart money isn't on beating Keytruda head-to-head. It's about capturing the patients where Keytruda fails. Even 10% of the liver cancer market = massive returns at current valuation. Plus if that 17% complete response rate holds in larger trials, Big Pharma will come shopping. Different mechanism + better complete response rate = acquisition bait. TL;DR: Not trying to replace Keytruda, trying to fix what it can't. At negative enterprise value, they don't need to win the whole market to print tendies 🚀

richbeezy

Shitty stocks that rose today for the sole reason of being heavily shorted. Ones that you could and should buy puts on: -ANGI -REAL -GEO -RUM -PD

jorge-emilio

I'll answer your question using the four points that I established in one of the yellow notes. The four points are the following: 1. Macro trend (is it clearly bullish or bearish?). 2. Macro PD Array (are there one or more PD Arrays that align with the macro trend?). 3. Micro signal / Mathematical logic (this would be your personal entry technique on whatever timeframe you use). 4. Trade the momentum that favors the macro trend (go with the macro trend, not against it). These are the criteria that I look/wait for in order make a high-probability decision. \*\*\* This is not financial advice and should not be used or considered as financial advice.

En_CHILL_ada

https://youtu.be/PD5gtM1A990?si=pHsdOLr7PzU6yRb3

Ikeelu

I also some one slow down for a deer crossing the street today and slow down to cautiously pass PD. The deer didn't show up on camera though which was surprising it still slowed down not registering it as an object on screen.

richbeezy

Here's the kicker, when markets get overbought (which they are getting close to), you keep your shares in high growth "Chad" stocks - but also buy lots of puts on SHITTY companies like BMBL, LUMN, REAL, GEO, RUM, PD, etc). Shitty stocks that are in a 5 year downtrend. Therefore, if the market keeps going higher - these shitty stocks will still struggle in comparison. Then when the market truly turns, these puts will print. The ones I have are out to 10/17, plenty of time for a correction between now and then and markets tend to trough in early/mid October. Yes, I've been doing this for a long time (almost 26 years now).

Possible_Cheek_4114

https://www.businesswire.com/news/home/20250618276691/en/FDAs-Approval-of-Keytruda-for-PD-L1-Positive-Head-and-Neck-Cancer-Patients-Signals-a-Clear-Pathway-for-CEL-SCIs-Multikine-to-Address-a-Major-Unmet-Need-in-PD-L1-Negative-Cancer-Patients

smutmybutt

I would say that example just proves that the Baltimore PD is fucking stupid. Any ineffective system can recommend people to arrest. I think Musk and Thiel are capable people who have compromised their own capability by falling so deeply into their ideology, self-absorbed echo chamber, and worst instincts (although Elon has the most publicly available evidence to back up this claim). In the case of Elon he has a long-term addiction to drugs that are negatively impacting his brain. There was also evidence of Elon being a bad manager in his “golden years.” His main talent was being a bully with VC money. By most accounts he was basically kicked out of PayPal. If Elon was smart he wouldn’t have needed to support the anti-EV party in order to avoid SEC trouble. If he was smart he wouldn’t have alienated his main customer base for Tesla, running the only EV brand with declining sales. If he was smart his multi-year head start producing cars in China would lead to his vehicles beating out BYD and other Chinese competition (companies run by smart people like Apple have no problem maintaining their first mover advantage in China).

North_Ad_4609

Just a PD my guy

richbeezy

Give me a few shitty stocks to buy puts on (out to 10/17). I already have 2 good ones (BMBL & PD). I am looking for weak stocks with little future growth. Not an over-valued tech play, as they still have nice growth.

No_Feeling920

Just in time for this regarded bean counter leadership kicking in. Like it ended well the last time INTC tried it. Truly regarded... [https://www.digitimes.com/news/a20250609PD227/intel-gross-margin-profit-policy-business.html](https://www.digitimes.com/news/a20250609PD227/intel-gross-margin-profit-policy-business.html) They will be wishing to have kept Gelsinger a couple years down the road.

Same-Brilliant2014

Live PD is already back

Danyzinho29

Voyager Therapeutics, a clinical-stage biotech developing treatments for serious neurological diseases, including Alzheimer’s disease and Friedreich’s ataxia – both of which have limited therapeutic options. Voyager’s lead clinical candidate is VY7523, a monoclonal antibody designed to target pathological tau (pTAU), a protein closely associated with the progression of Alzheimer’s disease. Intended for early-stage intervention, the therapy has shown encouraging preclinical results. In mouse models, its murine surrogate demonstrated high selectivity for abnormal tau while sparing healthy tau and delivered strong efficacy in the P301S seeding model, a benchmark in Alzheimer’s research. Voyager recently completed a Phase 1 single ascending dose (SAD) trial in healthy volunteers and has since launched a multiple ascending dose (MAD) trial in patients with early-stage AD. Topline SAD results were positive, showing that VY7523 was well tolerated across dose levels and achieved expected central nervous system exposure. Alongside its antibody-based approach, Voyager is also advancing a gene therapy pipeline powered by its proprietary TRACER capsid technology. These engineered capsids are designed to deliver therapeutic payloads directly to brain cells while minimizing off-target exposure in tissues such as the liver. Among these programs is VY1706, a tau-silencing gene therapy intended to suppress pTAU production in neurons for the treatment of Alzheimer’s. At the 2025 AD/PD conference, Voyager presented encouraging non-human primate data showing that a single intravenous dose of VY1706 achieved dose-dependent, robust reductions in MAPT mRNA and tau protein across critical brain regions. An Investigational New Drug (IND) filing remains on track for 2026. The promise of Voyager’s TRACER platform has attracted major pharmaceutical partners. Through deals with Neurocrine Biosciences, Novartis, and Alexion (a subsidiary of AstraZeneca), the company could earn up to $7.4 billion in milestone payments. The Neurocrine collaboration is already advancing gene therapy programs for Friedreich’s ataxia and GBA1-related disorders, with IND filings expected in 2025 and clinical trials slated to begin in 2026. Voyager could receive up to $35 million in milestone payments tied to these near-term milestones. Source: TipRanks

the_whole_arsenal

By waiting in the wings, you mean 3-4 years before it reaches its next-generation phase design, 5-6 years before it is on the wing of a plane, and 8 years before it is certified outside China, right? From what was said about it at the Dubai Airshow in 2024, the first-generation engine has serious power deficiency issues. It needs 28,000 lbf to make the c919 airborne, and testing has it in the 25,000 to 26,000 range. The LEAP engine produces 30.8k to 31.6k lbf in thrust depending on the model. The CJ-1000A is closer in architecture to the CFM-56-5 (an engine designed 38 years ago) than the LEAP with an 8.5x bypass ratio and suggests it would be limited to ~27,000 max thrust. China would honestly be better off contacting United Engine Corp (Russian) and offering a boatload of cash for a turnkey design to build the Aviadvigatel PD-14 under contract. It is 6-8 years more mature in design than the CJ-1000A, but I'm sure I'll hear a lot about both next week in Paris.

Formal-Industry-5243

I recently came across a relatively small biotech company called Faron Pharmaceuticals (FARN on AIM, FARON on Nasdaq Helsinki), and I wanted to share some thoughts and hear opinions from others who follow the biotech space. Faron is a Finnish biotech company developing immunotherapies for the treatment of aggressive cancers and inflammatory conditions. Their lead candidate, bexmarilimab, is a macrophage-targeting antibody (anti-Clever-1) currently in clinical trials for several types of solid tumors, including NSCLC, HNSCC, and melanoma. The early data from the BEXMAB trial (combination with anti-PD-1/L1 therapies) shows some promising responses in difficult-to-treat cancers. Here are a few points I found interesting: • Unique Mechanism: Bexmarilimab aims to reprogram tumor-associated macrophages (TAMs), potentially enhancing the patient’s immune response against cancer. • Small Cap: The company is still quite under-the-radar, with a market cap under €200M, which leaves room for volatility but also upside. • Funding: Like many small biotechs, they face financing risks. They’ve had a few rounds of fundraising, and dilution is a concern. • Upcoming Catalysts: More clinical readouts expected in 2025 – could be make-or-break depending on data. I’m curious: • Has anyone here been following Faron? • Thoughts on the BEXMAB trial or the TAM-targeting approach? • Is this a potential hidden gem or just another risky small-cap biotech? Would love to hear others’ DD or bear/bull theses!

Beneficial-Swim843

Yeah, because there aren't any names that aren't pennies that move far more often and more significantly LMFAO  NTAP, PATH, ESTC, PD, AMBA, MRVL, AEO, ULTA, ZS, etc. https://preview.redd.it/2ll26rsvbx3f1.png?width=495&format=png&auto=webp&s=180b56205e500bab6ad7bd85cef4231c0a33cfdc

richbeezy

Bought PD puts. Who even uses a pager any more???? /s

richbeezy

PD (been in biz for so long and struggles to make profits in an environment/sector where it should be easy). BMBL - no need for explanation. DIS - dying company, chart looks like 💩 JETS - airline ETF, ppl are flying less overall. QBTS - bought puts Friday, just over-valued short/intermediate term.

f0xinaround

Campus pd or live PD?

richbeezy

Bought some puts on DIS, QBTS, JETS, and PD. Just hedging my long portfolio.

Gloomy_MTTime420

Yes, you have to go alone and setup your own Discord server. It’s the only way! This chat sucks, feels like it’s been taken over by bots, young inexperienced investors, PD guys like that GodMyShield clown, or the same two people answer everyones’s posts (which by its very definition becomes homogenized). And most people here imo (and no offense to those of you this applies to), have absolutely zero clue what they are doing. Would you take driving lessons from a 7yr old that just learned how to ride a bike without training wheels? Yeah, it’s like that.

BenisSpaghetti

This is why you must stay vigilant and report any 🐻 activities to your local authorities. I reported my coworker after he said he won't be able to retire due to being 'out of the market'. Luckily the local PD came by and shot him in the back of his head while he was working. Solved that retirement problem for him! 

Gloomy_MTTime420

If you are attempting to trap retail traders in an upside down OTC stock, keep listening to all the PD about $DMN!

Gloomy_MTTime420

At least the pennystock sub has better picks than the constant stream of PD posts from shortsqueeze.

IdealShot7890

and still not getting the love here. we are all busy chasing risky Chinese PD plays

Kestrel19

I just did a quick read and the two (ANVS & AVXL) are different in target molecules and mode of action. ANVS is effectively an mRNA inhibitor. go to wiki to learn about Blacarmesine. My own view is the mitochondria play a substantial role in PD. Hopefully we will one day see a pinch of Blacarmesine added to Buntanetap in a trial.

jefbe80

7:09 AM EDT, May 06, 2025 (Benzinga Newswire) License Expands Genprex's Portfolio of Oncology Gene Therapy Technologies AUSTIN, Texas, May 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive patent license agreement with UTHealth Houston granting Genprex exclusivity and commercial rights relating to its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the potential treatment of glioblastoma. The subject patent is co-owned by Genprex and UTHealth Houston, and the license provides Genprex with patent exclusivity. "We are pleased to expand our portfolio of licensed patents and add a technology that uses REQORSA to treat glioblastoma," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. "With this license agreement, Genprex has obtained exclusive commercial rights to REQORSA in glioblastoma while also adding to our patent estate. The role of TUSC2 in lung cancer has been well established, and this latest license enables Genprex to expand the use of REQORSA into a new indication, in which the cancer can be difficult to treat and there are unmet medical needs." REQORSA may be a potential therapeutic treatment for glioblastoma. Genprex previously reported positive preclinical data on the efficacy of REQORSA in glioblastoma in October 2024 at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Research collaborators from UTHealth Houston previously reported TUSC2 as a novel tumor suppressor for glioblastoma, the most common and deadliest primary brain tumor in adults which is associated with a poor prognosis. In their latest study, UTHealth Houston researchers used patient-derived glioblastoma (GBM) cell lines and patient-derived glioma stem cell (PD-GSC) lines. REQORSA was used to restore TUSC2 expression. Write to Benzinga at editorial@benzinga.com

Duke834512

Didn’t he fire Jeff Bridges the first time around for threatening to do that shit? I vaguely remember the Keebler Elf threatening legal states and getting salty when they threw up the finger and said “The DEA won’t have any help from local PD” Could be misremembering though

YamahaRyoko

It was our PD's #1 probable cause tool. They even pleaded on Facebook not to vote for legalization, claiming they have "never bullied the public with it". Yeah right lol

JohnLaw1717

Iirc robotaxis are just a taxi service using normal Tesla's. That deploys in a couple weeks in Austin. They already hired the drivers and Austin PD has had press conferences and stuff. You're probably trying to joke about cybercab. Thats the vehicle specifically designed for being a taxi. It's unconfirmed but there's drone footage of hundreds of chassis or frames rolling out to the Tesla factory yard for initial testing already.

narrowant34

They are yapping that leather jacket man is considering spinning off his company's Chinese operations or establishing a joint venture in China. [Link](https://www.digitimes.com/news/a20250428PD215/nvidia-jensen-huang-ai-chip-china-geopolitics.html) [Link1](https://x.com/Jukanlosreve/status/1916740717638029503) 

mmcmonster

This is one of those things that really depends on when your starting points are. Here is [Gold vs. US Stock Market since 1980](https://testfol.io/?s=7BBKer6sBhf). Here is [Gold vs. US Stock Market since 2000](https://testfol.io/?s=b56APv2PD49). Here is [Gold vs. US Stock Market since 2020](https://testfol.io/?s=9PoWJUAUES3). Make an [Investor Policy Statement (IPS)](https://www.bogleheads.org/wiki/Investment_policy_statement) and stick by it. It's not as sexy as buying high and selling low, but it will do you better in the long run.

ChairmanMeow1986

Soo, if you don't grasp PD.T I'd say don't day trade on margin. if you don't understand something it is time to learn.

hynekien

https://x.com/unusual_whales/status/1914794137997476134?s=46&t=AX7Lo0mD5PD0A7kSIgJZ4w

jxx37

Obviously you also need SW to support HW--the critical speed difference is the dedicated HW build. Most of the people from the HW side that who moved to high speed trading work on FPGAs. Interestingly one of the big companies in the field recently hired a full digital PD team with 4nm experience so at the minimum they are exploring doing custom silicon.

warlock22041

I have been paged 4 nights in a row. If I get paged one more time tonight, PUTS ON PagerDuty PD 

tenpenny3

As someone in the food tech space, Wendy’s has a really good app. While McDonald’s app is OK but their loyalty and overall complexity holds them back. Notice that wendays has in-store (or at least close to it) pricing while McDonald’s still uses their 3PD pricing? McDonald’s App is a mess. Their app is hard to navigate, their loyalty shit, and their app pricing makes a DoorDash dash pass make sense (not a good thing for first party).

wiggitywoogly

Paradise PD did it, why can’t we?

geneing

I don't think the trade deficits are real. At least, they are not measured correctly. For example, an iPhone is $1000. Assembly and parts cost about $400 (https://www.digitimes.com/news/a20241004PD214/apple-iphone-component-cost-production-profit.html#:~:text=The%20bill%20of%20materials%20(BOM,up%2016%25%20of%20the%20BOM.) The rest is the cost of design, software, IP that was created in the USA. Even for many parts the value is mostly created in the US (eg Qualcomm modems, memory and storage). When this iPhone is sold in the rest of the world, it effectively exports hundreds of dollars of added value created in the US.

pandadogunited

>The problem isn’t people assuming the market will give good returns in a decade or two. That’s almost certain.  It’s not almost certain, though. There have been multiple decade+ periods where the market was flat. I know [1901-1920,](https://testfol.io/?s=37zzndvPNPF), [1929-1943](https://testfol.io/?s=fTKrh0PD0nE), [1966-1984](https://testfol.io/?s=76qwMr5Q0AU), and [2000-2013](https://testfol.io/?s=deJdJD4Kmo1) off the top of my head, so there are probably more.

leesteapleton

That Garcia wifebeater was involved in a human trafficking stop in 2022 in TN where the FBI had to step in and tell the local PD to piss off. That’s why they care about him and not the other thousands of others getting the boot

kittypryde123

PD not ID

alefkandra

calls on $PD then cuz any on call dev is being paged to fuck right now

Strickschal

> We will see about that… We already ARE seeing about that. If we look at Germany, net migration is only around 2000 people per year and the trend of the absolute numbers is negative, which I wouldn't expect to change anytime soon. Also, more US americans move to Germany than Germans move to the US. https://www.destatis.de/DE/Presse/Pressemitteilungen/2024/10/PD24_N048_12_91.html > traditionally, people move to where they can make the most money as long as they have the opportunity to actually move. Is that so or is that just what you believe? Again, there are lots of reasons besides money to not move halfway across the world in general and to not move to the US in particular. > I know many a European that lives in the US working high paid jobs, they only came here in the first place because of the money and opportunity. Many more try to come to the US after school, then have to move back and work the same job in Europe making half as much. Sure these people exist, but drawing the conclusion that there's no people left here who could develop alternatives to Google, Amazon and whatnot is quite the leap, to say the least.

Captain_of_Gravyboat

The cost to manufacture an iPhone is around $500. https://www.digitimes.com/news/a20241004PD214/apple-iphone-component-cost-production-profit.html Before tariffs they were getting about 60% profit margin on the sale of the phone itself (not including services, subscriptions, kickbacks from carriers for exclusives, etc..) so im pretty sure they will be ok and will be quite thrilled if people are ready to pay $2300. The tariff will be on the declared value of goods at point of import (basically cost + shipping), not on the retail price.

yuseyername

Sorry don’t know where to post this. OP keeps sexually harassing my backyard chickens. Pittsburgh PD said they can’t do anything about it yet, but I want you guys to know OP keeps sneaking into my yard to fuck my chickens.

x_Carlos_Danger_x

DOGE cuts and donuts finally caught up the local PD 🚔

chargedcapacitor

Dallas PD covered it up because of their gigantic lack of competence. It's not even a secret, they keep some of the records sealed because some of the idiots or their families are still alive and the government doesn't want to put them in harms way

BumblesAZ

I’m sure the HOA’s are going to have a field day with issuing violations on the residential farms. Also, that’s not to mention the nuisance calls the local PD’s are going to deal with when the boomers start calling on their neighbors about blowing chicken shit. lol

North_Ad_4609

I took a lot of beating trying to tell people that this was a bad PD based on nothing but lies. It pumped like they always do and dumped really hard too. This was the making of that op Best_phone.

eddie991ao

Tacoma PD will make you cry

MoonsofPluto

I've just realized I had the most ridiculous run of luck then , I wasn't really paying much attention to the economy except the news were always banging on about banks and all that stuff. I managed to double my salary 4 x almost in a row during that time. I went from £22k a year 2008 as a junior to £42k a year moving jobs 2009 then went free lancer contracting and made more than double again £400 PD 2010 and 2011. I then went to Switzerland in 2012 and after tax was earning about double the amount again because it was a great rate and the tax rate there is so low.. I've never earned as much since then. Which was 2014

mountainoftea

Here's an interesting tidbit: [https://www.digitimes.com/news/a20250305PD239/psmc-himax-display-manufacturing-technology.html](https://www.digitimes.com/news/a20250305PD239/psmc-himax-display-manufacturing-technology.html)

wambulancer

Ah yes the time-honored tradition of PDs taking huge white elephant boondoggles that do nothing but drain resources You gotta be a grade-A moron police chief to accept these things when they'll be waterlogged paperweights within a year if given the usual PD maintenance schedule

WildConsideration376

Lunr had a warrant out for arrest by the stock market police..so they decided to call the PD and pay the fee for the warrant to avoid getting arrested on the way to Wendy's work shift.Thanks..and you are welcome

_Christopher_Crypto

They did it last time I was there. We always use the app to scan and pay, we still have to wait in the line with all of the checkout users. They will scan their items but not ours. It would be great if they opened both sides of the tower and let self checkout walk through. The one we frequent has the local PD there arresting shoplifters more often than not so that may be a deterrent for them.

kidfromtheast

So, 5 days ago there is delivery delays and actual yield issues of GB200. Now, we magically have tons of GB200 chips repurposed for 5090? Are we willing in the world magic? https://www.digitimes.com/news/a20250211PD210/quanta-foxconn-nvidia-blackwell-2025.html

therev012

if you’re new to trading then you gotta know what you wanna do. Do you want to invest and forget and not worry? Then buy etfs or bluechips with growth. Like rn PLTR is on the rise and their market cap still has room to grow. But they’re at an ATH so I would wait for a dip. On the chart there is a major gap on the daily chart so there is a chance it could fall to close that gap. VOO and SCHD are solid etfs to buy and hold forever. SCHD especially during a bear-market. If you want to trade on trends, look at the news. I made a nice chunk of change on Digital Ally back during COVID because of the riots. I bought because they make police body cams and Kansas City PD made a big order with them so the price jumped a bit. Only made like $300 but still, predicting things regarding news is risky but can have pay-offs. Reverse splits aren’t good (most of the time) because the company is diluting their shares. Stock splits are good because the price gets cut, adding shares to your portfolio (if you own some) while also making the price more approachable for anyone who wants to buy. There’s a reason that biotech company hasn’t seen their ATH in years… Don’t gamble on companies unless you have done your research and/or you believe in them for one reason or another.

Nuzina

Check out this news article 👀 Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer https://www.prnewswire.com/news-releases/genprex-collaborators-find-nprl2-gene-therapy-using-oncoprex-delivery-system-is-a-potential-treatment-for-anti-pd1-resistant-non-small-cell-lung-cancer-302375899.html

Aggravating-Drag-207

GNPX - Great news: Chatgpt: "The recent publication highlighting the efficacy of NPRL2 gene therapy in anti-PD1 resistant non-small cell lung cancer is a promising development for Genprex. However, this positive news has not yet translated into an increase in the company's stock price." Good price to get in, volume already gone up! GNPX is the play for today

nughit

The Ca Irvine PD hates Tesla cop cars especially the cyber truck

romt_25

Three proposals the United States has presented to TSMC. 1. TSMC would build an advanced packaging facility in the US, offering integrated services from wafer manufacturing to backend processing locally. 2. Under a joint venture (JV) proposed by the US government, TSMC along with several major companies would invest in Intel’s standalone foundry business and facilitate a technology transfer from TSMC. 3. Intel would assume future packaging contracts from US customers that TSMC has secured, leveraging Intel’s advanced packaging capabilities. [https://www.digitimes.com/news/a20250212PD234.html](https://www.digitimes.com/news/a20250212PD234.html)

its-me-reek

Active like a yr ago, then I let the things go into motion. https://www.reddit.com/r/wallstreetbets/s/jqULbfD7PD (Master piece) https://www.reddit.com/r/wallstreetbets/s/MOJq2Gmuhg (Everyone wrong lol) Back again if this works no more reek I'll fade away. $hood is going to $100+ like those tech stocks from 2020 (sq, shop, pypl etc) and my balls r tucked along for the ride

Foreign-Coconut3500

Ya never seen an American civilian hobbled by local PD and thrown in the back of the van?

mlbnva

What I originally said may have underestimated the rapid pace of innovation we're seeing today, or perhaps was misinterpreted. The recent news illustrates a major shift in the AI hardware and algorithm landscape. On one hand, DeepSeek’s breakthroughs have shown that with clever architecture and optimization, you can achieve up to a 57× improvement in inference efficiency compared to traditional approaches on Nvidia GPUs. This challenges the long–held assumption that Nvidia’s GPUs are the only viable option for high–end AI applications—even though Nvidia still dominates the training side of things. But that’s not the whole story. In a separate, equally impressive development, Chinese researchers from Shenzhen MSU-BIT University have unveiled a new computational algorithm tailored for peridynamics simulations—a key tool in modeling material fractures and damage. Their “PD-General” framework reportedly boosts performance on Nvidia GPUs by up to 800× over conventional serial implementations (and about 100× faster than typical OpenMP–based parallel programs). Importantly, this breakthrough isn’t from Nvidia at all—it’s an independent innovation driven entirely by algorithmic ingenuity. Combined, these advances underscore a broader trend: significant performance gains in both AI inference and scientific computing are now achievable not just through hardware upgrades but through smarter, more efficient algorithms. This means that even if Nvidia’s GPUs remain essential for training huge models, the overall demand for compute—in both training and inference—could evolve dramatically as more players adopt these cost– and energy–efficient approaches. In short, while Nvidia continues to be a key player, the rapid pace of innovation—both in hardware alternatives and in algorithmic breakthroughs like the 800× speedup—suggests that the AI ecosystem will look very different even in just a year. The market is diversifying, and the old assumptions about compute requirements are already being rewritten.

BryceJettESG

My best trading advice: the "read books" thing isn't bullshit, go and read books now! That will help you so fucking much, I used to think YouTube vids and similar could replace this. But hell no. I recommend Larry R. Williams books. My best PD advice: you have to visualize whatever you desire. Believe you'll get there, don't doubt it for a second and you'll get there. A good book about this is "The Secret".

FindingShot3247

Is HCWB PD? It’s tanking

alderson710

How many INTC stocks do you own? For low budget GPUs, AMD will definitely experience huge growth from it, more than INTC imho. PD: I don't own INTC or AMD.

FollowingCalm

I unfortunately got caught in what appears to be a PD Was told 14. Was a good buy. Currently holding 5,000 Shares. Any advise?

notyourregularninja

PD going Tesla cars and SuVS gonna bump Tesla stocks?

Enough-Mud3116

Doctor here, PD-L1 agents are competing against other checkpoint blockade such as CTLA-4 and PD-1, and seems like their main product is that. Hope your bet works off but hard to prescribe a drug called Unloxcyt when you have trademark names like Keytruda or Opdivo.

Phoenixchess

This FDA approval is massive for CKPT. They're targeting a [$1 billion market](https://finance.yahoo.com/news/fda-approves-checkpoint-therapeutics-skin-142201452.html) with Unloxcyt - the first PD-L1 blocker approved for cutaneous squamous cell carcinoma. Big advantage being first to market here. The short interest setup looks juicy too. 20% of float shorted with only 1 day to cover. Those 3M shares of insider buying definitely adds pressure. But let's be real about the risks. Their cash position is tight - only $4.7M in cash with negative working capital. They'll need more funding soon to commercialize Unloxcyt properly. Expect dilution or partnerships ahead. That said, the biotech sector loves these FDA approval + high short interest plays. Look at what happened with MESO after their recent approval. This has serious potential for a squeeze, especially with that 66% off-exchange short position needing to cover. Your options play seems solid with that January 2025 expiry. Gives plenty of time for the thesis to play out while limiting downside risk compared to shares.

wrxst1

FDA approved their newest drug UNLOXCYT for human use, it’s the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma. They project more than 1 billion in revenue annually. Why shorts haven’t started to close is wild. This is break through. This drug can be used for patients who don’t qualify for radiation or surgery.

ExpeditedLead

Oh wow lol. Just searched on twitter. Police have indeed confirmed. Also said PD didn't fire weapon, so either took their own life or school guard. Usual suspect, but they keep spreading and encouraging mentally ill rhetoric under the manipulation and guise of inclusion & "peace"

charlsey2309

There’s multiple different PD-1/PD-L1 initiators out there beyond keytruda, crowded market.

Tastee_Stuff

I'm sorry . This is not small news. "Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication." Squamous cell carcinoma is very common and important cancer to control, Being the first one and only PD-L1 blocking anybody is huge in my opinion. I can't understand the stock movement but I don't see how a huge pharma wouldn't want to partner or take over paying obscene money for it. I'm at 10000 shares at $3.98 We will see how this unfolds

samTHEgutterman

That's funny. I was telling a buddy the same thing yesterday. Imagine how bad the L.A.P.D would want a evTOL. I've read before also PD's really struggle to keep their birds in the air with the price of fuel. Guess it's super expensive to gas up a choppa

trainwreck001

EVERY PD is going to have a VTOL with all kinds of electronics and shit. Bad Boys... Bad boys... 🎶🎶🎶 

Substantial-Read-555

Yes, there will be a pump. But as comped to keytruda I believe a LT play as well. https://ca.finance.yahoo.com/news/checkpoint-therapeutics-announces-fda-approval-231500549.html UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -...

sonofalando

Nintendo about to sue Pennsylvania PD 

Former_Librarian_576

Because it’s a cell therapy not a traditional drug, need to have a lab set up to concentrate the process the cells. Also it’s not first line at those stage and is only used for melanoma patients who have failed PD-4 therapy, but shows pretty good response rates in those patients.

BULLSONYA

RXRX to report: Phase I monotherapy safety and pharmacokinetic and pharmacodynamic (PK/PD) data for REC-617 on Dec. 9 during the American Association for Cancer Research special conference in Toronto - RXRX has a 20 billion pipeline guarantee. Leader in AI drug development, and just bought their competitor.

paulyh4444

Thanks! Yes, that is an important point. I'm hopeful the FDA approves it just from a humanity perspective. A few other pretty promising ALS trials are currently going on, but CNM-AU8 is the closest to getting to actual people. The MS results were awesome! Remyelination would be huge, I don't think there is a drug that currently does that. I'm hopeful this class really changes neurodegenerative disease treatment. I haven't researched the PD trials much, but I also think they had some good news!

BULLSONYA

RXRX to report: Phase I monotherapy safety and pharmacokinetic and pharmacodynamic (PK/PD) data for REC-617 on Dec. 9 during the American Association for Cancer Research special conference in Toronto - RXRX has a 20 billion pipeline guarantee. Leader in AI drug development, and just bought their competitor.

BULLSONYA

RXRX to report: Phase I monotherapy safety and pharmacokinetic and pharmacodynamic (PK/PD) data for REC-617 on Dec. 9 during the American Association for Cancer Research special conference in Toronto - RXRX has a 20 billion pipeline guarantee. Leader in AI drug development, and just bought their competitor.

blackSwanCan

Also, Blackwell Ultra production has been brought forward. Besides Nvidia, two other winners could be [SK Hynix](https://www.digitimes.com/news/a20241008PD212/sk-hynix-samsung-hbm-production-micron.html) which leads in HBM4 production, and TSMC which has scaled its processes to allow 12 HBM4 memory stacks, and other suppliers who can scale HBM4 production.

thirtydelta

Phase I monotherapy safety and pharmacokinetic and pharmacodynamic (PK/PD) data for REC-617 on Dec. 9 during the American Association for Cancer Research special conference in Toronto

rockettilt

PD beat lfg

nestor330

My AMBA PD and NTNX calls are good. Dell beat but I guess not enough

nestor330

My AMBA PD and NTNX calls are good. Dell beat but I guess not enough

noiserr

AMD has already sold over $5B worth of mi300x, in its first year. ROCm has been improving a lot. In fact for large models like Llama 3 405 billion parameter model, Meta runs inference exclusively on mi300x because AMD GPUs have more vRAM. https://i.imgur.com/II7nnqa.png There are even tools which you can use to run straight CUDA on AMD's hardware. This is an open source project, but there are also commercial solutions: https://github.com/vosen/ZLUDA So CUDA is not the moat you think it is. You think Nvidia is more likely to reach a $7T market cap than AMD is able to reach a $500B market cap? I don't. I think AMD is more likely to reach the $1T (4x) market cap before Nvidia reaches $7T (2x) market cap. We also know Nvidia currently enjoys a 85% market share. But at TSMC they have [60% of the COWOS](https://www.digitimes.com/news/a20241122PD200/nvidia-tsmc-capacity-cowos-2025.html) packaging capacity for the next year. Take a wild guess who has most of the rest of that 40% capacity?

spkincaid13

I looked up some of the wealthier suburbs of indy and starting pay for PD's is under $70k

Standard-Inflation-6

This is an investing forum. Did my stocks go down, no, did my financial situation deteriorate, certainly not. Becoming much more political and crazy horrible politicians is all your (incorrect and nonsense) opinion, certainly not realism. The Biden administration was absolutely rubbish, prioritising DEI and similar woke BS over the actual wellbeing of the people and making genuine economic / technological progress. There’s a reason Trump won in a landslide, even with all 99% of the mainstream media framing him as the next Hitler [Biden’s wonderfull achievements](https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcTrc-b-Pv6pB-Fpb8PD8mYwan-EYBHTvbT5eVTX-KfYs40pNGWMUulOe6M&s=10)

xShiftfaced

My economics professor.. YEARS ago was escorted out by the entire university PD for child pornography and he was held at high standards. Crazy. So I get it

3ebfan

\>Applied science is well established in academia and scientists and physician scientists are well abreast of their fields and are well able to design trials. I respectfully disagree here. Applied science is good in some areas but is especially poor in other less understood but highly needed areas, such as the neurosciences. Doctors learned more about AD from the commercial failure of Aduhelm than they ever learned about AD in a lab, specifically, the efficacy being time and dose dependent, which researchers did not know despite studying AD for many decades. Aduhelm was a drug that was approved on mixed data yet resulted in very decorated doctors resigning from the FDA because they didn't agree with the premise on approving the drug with spliced data. This controversy ultimately led to the drug being shelved. I would argue the rigorousness of the FDA has held back AD and PD research for at least the last 20 years.

swampassOG

Sounds completely legal and unlikely to have you cuffed and molested by the local PD

_my_other_side_

Dump it into PD (pipe dream)

Alex_Trenholm

$PD

Ol_Maxxie_Solt_DB

This is a weird but true stat: Once a drug developer eclipses a $100 billion valuation, it almost never outperforms the S&P 500 in total returns (including dividends). Drug development is a different animal. The need to continuously replace revenue churn puts a valuation ceiling on drug developers and limits them from scaling. In Merck's case, Keytruda loses core patent protection later this decade. I think PD-1 drugs will be able to protect themselves as subcutaneous presentations emerge, but there are better bispecific antibodies in the global pipeline now, too. Keytruda is the bestselling drug of all time by annual revenue by a significant margin. In 2023, the second bestselling drug was almost $10 billion behind.